Product name: L-Hydroxyproline
Synonym name:
Catalogue No.: BP3523
Cas No.: 51-35-4
Formula: C₅H₉NO₃
Mol Weight: 131.131
Botanical Source:
Physical Description:
Type of Compound: Amino Acids

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle

Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.

The product could be supplied from milligrams to grams
Inquire for bulk scale.

For Reference Standard and R&D, Not for Human Use Directly.

Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

L-Hydroxyproline (CAS number: 51-35-4), also known as (2S, 4R) -4-hydroxypyrrolidine-2-carboxylic acid, is a non-standard protein amino acid that mainly exists as a component of structural proteins such as collagen and elastin in organisms. Unlike the common 20 standard amino acids, L-hydroxyproline is not directly synthesized by ribosomes, but is generated by hydroxylation of proline residues catalyzed by prolyl hydroxylase (PHD) during post-translational modification. This unique biosynthetic pathway endows L-hydroxyproline with irreplaceable functions in maintaining protein high-level structure, regulating cell signal transduction, and participating in metabolic regulation.

In the field of natural product chemistry and pharmacology, the research value of L-hydroxyproline is reflected in multiple aspects. Firstly, it is one of the most abundant amino acids in collagen, accounting for approximately 13-14% of the total amino acid composition of collagen. Its content level directly reflects the activity level of collagen metabolism. Therefore, the concentration changes of L-hydroxyproline in blood and urine have become important biomarkers for clinical evaluation of bone metabolism diseases, liver fibrosis, and tumor invasion and metastasis. Secondly, L-hydroxyproline and its derivatives have shown potential pharmacological activities in areas such as anti fibrosis, anti-tumor, bone repair, and neuroprotection, making them a hot molecular backbone in new drug development. In addition, as a chiral synthetic block, L-hydroxyproline has a wide range of applications in asymmetric synthesis, pharmaceutical intermediates, and functional material preparation.

In recent years, with the deepening understanding of the collagen metabolism regulatory network, the biological function of L-hydroxyproline has expanded from a simple "structural component" to a "signaling molecule" and a "metabolic regulator". Especially its close association with the lysyl hydroxylase (PLOD1, PLOD2, PLOD3) and lysyl oxidase (LOX, LOXL1) families reveals the core position of L-hydroxyproline in collagen cross-linking, extracellular matrix remodeling, and tumor microenvironment regulation. This article will systematically review the research progress of L-hydroxyproline from the aspects of chemical structure, plant origin, pharmacological activity, molecular mechanism, medicinal properties, and clinical application prospects, in order to provide reference for the in-depth development and transformation of this natural product.

Chemical structure and physicochemical properties

Chemical structural characteristics

The molecular formula of L-hydroxyproline is C ₅ H ₉ NO3, with a molecular weight of 131.1310 g/mol. Its core structure is a pyrrolidine ring, which is connected to a carboxyl group at position 2 (C2) and a hydroxyl group at position 4 (C4). The carbon at position 2 is in the S configuration, and the carbon at position 4 is in the R configuration. Therefore, its system is named (2S, 4R) -4-hydroxypyrrolidine-2-carboxylic acid. This specific stereoconfiguration is the structural basis for the biological function of L-hydroxyproline. Compared with proline, the introduction of the C4 hydroxyl group significantly changes the conformational preference of the ring, making the pyrrolidine ring more inclined towards the C4 endo conformation. This conformational change is crucial for the stability of the collagen triple helix structure.

L-hydroxyproline exists in the form of zwitterionic ions under physiological pH conditions, with carboxyl deprotonation (- COO ⁻), amino protonation (- NH ₂ ⁺), and a net charge of zero. This zwitterionic property gives it high water solubility and low fat solubility. The analysis of tautomers showed that L-hydroxyproline mainly exists in the form of trans-4-hydroxy-L-proline zwitterionic species, and its intramolecular hydrogen bonding network further stabilizes this configuration.

Physical and chemical property parameters

According to the evaluation data of drug properties, the key physicochemical parameters of L-hydroxyproline are as follows:

• molecular weight：131.1310 Da， Belonging to the category of small molecule compounds, it is beneficial for transmembrane transport and oral absorption.
• Lipid water partition coefficient (LogP)-3.0620 indicates that the compound has strong hydrophilicity and extremely high solubility in aqueous phase, while it is almost insoluble in organic phase. This characteristic determines that its distribution in vivo is mainly limited to extracellular fluid and plasma, making it difficult to penetrate the lipid bilayer.
• Topological Polarity Surface Area (TPSA)69.5600 Å ², mainly contributed by carboxyl and hydroxyl groups. According to the "Rule of 5" principle, compounds with TPSA less than 140 Å ² typically have good oral bioavailability, but the TPSA of L-hydroxyproline is at a moderate level, suggesting that it may be absorbed through active transport or paracellular pathways.
• Water solubility：181.2115 mg/mL， It belongs to compounds that are highly soluble in water, which is advantageous for their development as injections or oral liquid formulations.
• Blood-brain barrier penetrability: Low. Due to its extremely low LogP and large polar surface area, L-hydroxyproline is difficult to passively diffuse through the blood-brain barrier, which limits its application in central nervous system diseases, but also reduces the risk of central toxicity.
• HERG inhibition: Negative. HERG potassium channel inhibition is the main risk factor for drug cardiac toxicity, and L-hydroxyproline has no hERG inhibitory activity, indicating its good cardiac safety.
• Ames test 0.6 (usually indicating negative or weakly positive). This result suggests that L-hydroxyproline did not exhibit significant mutagenicity in bacterial reverse mutation assays and had a low risk of genetic toxicity.

Spectral characteristics

The infrared spectrum of L-hydroxyproline shows that the C=O stretching vibration peak of carboxyl group is located at 1720-1740 cm ⁻¹, the O-H stretching vibration peak of hydroxyl group is located at 3200-3500 cm ⁻¹ (broad peak), and the N-H bending vibration peak is located at 1550-1650 cm ⁻¹. In the nuclear magnetic resonance hydrogen spectrum, the chemical shift of H α (C2-H) is about 4.4 ppm, the chemical shift of H γ (C4-H) is about 4.2 ppm, and the chemical shifts of H β and H δ are in the range of 2.0-3.5 ppm. In mass spectrometry, the molecular ion peak [M+H] ⁺ is m/z 132.1, and the main fragment ions include m/z 86.1 (loss of HCOOH) and m/z 68.1 (further dehydration).

Plant sources and extraction methods

Plant-based

L-hydroxyproline is widely distributed in nature, but mainly exists in bound form in collagen and elastin, with extremely low free content. In the plant kingdom, L-hydroxyproline is not a commonly present free amino acid, but rather exists as a component of cell wall glycoproteins such as elastin and arabinogalactan proteins. The plant sources rich in L-hydroxyproline mainly include:

1. Leguminous plants In seeds and seedlings of soybeans (Glycine max), peas (Pisum sativum), and alfalfa (Medicago sativa), cell wall proteins contain a high proportion of L-hydroxyproline.
2. Poaceae plants The content of L-hydroxyproline in the endosperm cell walls of wheat (Tritium aestivum), maize (Zea mays), and rice (Oryza sativa) varies with developmental stages.
3. algae The cell wall glycoproteins of green algae (such as Chlamydomonas reinhardtii) and red algae are rich in L-hydroxyproline.
4. medicinal plants L-hydroxyproline has been reported as one of the active ingredients in some traditional medicinal plants such as Astragalus membranaceus, Glycyrrhiza uralensis, and Panax ginseng.

However, the efficiency of directly extracting L-hydroxyproline from plants is low and the cost is high. At present, the main industrial method for obtaining L-hydroxyproline is through the hydrolysis and purification of animal derived collagen proteins, such as pig skin, cow bone, and fish scales. In addition, microbial fermentation methods (such as using recombinant Escherichia coli or yeast to express prolyl hydroxylase) have also become important production pathways.

Extraction and purification methods

Acid hydrolysis method

Acid hydrolysis is a classic method for extracting L-hydroxyproline. Hydrolyze collagen rich animal tissues (such as pig skin and cow tendon) in 6 M hydrochloric acid at 110-120 ℃ for 24-48 hours to completely degrade the protein into amino acids. After decolorization and filtration with activated carbon, the hydrolysate is separated by cation exchange resin (such as Dowex 50W-X8). L-hydroxyproline is eluted together with neutral amino acids such as proline and alanine, and further purification is required by preparative high-performance liquid chromatography (HPLC) or crystallization method. This method is simple to operate and cost-effective, but tryptophan and cysteine are destroyed during the hydrolysis process, and a large amount of acidic waste liquid is generated.

Enzymatic hydrolysis

Enzymatic hydrolysis uses specific proteases (such as collagenase, trypsin, pepsin) to hydrolyze collagen under mild conditions (pH 2-8, temperature 37-50 ℃). Compared with acid hydrolysis, enzymatic hydrolysis has milder conditions, no damage to amino acids, and higher product purity, but lower hydrolysis efficiency and higher enzyme cost. The commonly used enzyme combinations include: initial hydrolysis by gastric protease (pH 2.0, 37 ℃), followed by further degradation by trypsin (pH 8.0, 37 ℃) or collagenase (pH 7.4, 37 ℃). The enzymatic hydrolysate was removed from the macromolecular peptide by ultrafiltration (molecular weight intercepted 3-10 kDa), and then purified by ion exchange chromatography and gel filtration chromatography.

Microbial fermentation method

In recent years, the production of L-hydroxyproline using genetically engineered microorganisms has become a research hotspot. In the future, proline hydroxylase genes (such as P4H) derived from animals or microorganisms will be cloned into Escherichia coli or yeast to achieve biotransformation of L-hydroxyproline using proline as a substrate in the presence of Fe ² ⁺, α - ketoglutaric acid, and ascorbic acid. The fermentation broth is centrifuged to remove bacterial cells, the supernatant is adsorbed by ion exchange resin, washed with ammonia water, and finally concentrated and crystallized. This method has the advantages of mild reaction conditions, environmental friendliness, and high optical purity of the product, but the fermentation period is long and the yield needs to be improved.

Detection and analysis methods

The qualitative and quantitative analysis of L-hydroxyproline mainly adopts the following methods:

• colorimetry Based on the oxidation of L-hydroxyproline by chloramine T to generate pyrrole, which reacts with p-dimethylaminobenzaldehyde (Ehrlich reagent) to produce a red compound, the absorbance is measured at 560 nm. This method is simple and fast, suitable for batch sample screening, but has poor specificity and is susceptible to interference from other amino acids.
• High performance liquid chromatography (HPLC)Using a C18 reverse phase column, ortho benzaldehyde (OPA) or 9-fluorenylmethoxycarbonyl chloride (FMOC Cl) was used as derivative reagents for fluorescence detection (excitation wavelength 340 nm, emission wavelength 450 nm). This method has high sensitivity and good specificity, and can simultaneously detect multiple amino acids.
• Liquid chromatography-mass spectrometry (LC-MS/MS): Electro spray ionization (ESI) positive ion mode and multi reaction monitoring (MRM) mode are used to detect the ion pairs of m/z 132.1 → 86.1 and m/z 132.1 → 68.1. This method does not require derivatization, has a short analysis time, and is suitable for trace analysis of L-hydroxyproline in complex biological matrices.

Pharmacological activity research

Anti fibrotic activity

Fibrosis is a common pathological feature of various chronic diseases, characterized by excessive deposition of extracellular matrix (ECM), with abnormal accumulation of collagen being the core link. L-hydroxyproline, as a unique component of collagen, plays a key role in the metabolic regulation of fibrosis process. Research has shown that exogenous supplementation of L-hydroxyproline can inhibit prolyl hydroxylase activity and reduce collagen synthesis through a negative feedback mechanism. In a rat liver fibrosis model induced by carbon tetrachloride, L-hydroxyproline (50-200 mg/kg/d, intraperitoneal injection) significantly reduced serum levels of hyaluronic acid, laminin, and type III procollagen, alleviated collagen deposition in liver tissue, and improved liver function indicators (ALT, AST). Similarly, in a mouse model of pulmonary fibrosis induced by bleomycin, the intervention group with L-hydroxyproline reduced alveolar septal thickening and hydroxyproline content (reflecting total collagen) by about 40%.

Bone metabolism regulation activity

Bone tissue is one of the organs with the richest collagen content, with type I collagen accounting for over 90% of the bone organic matrix. L-hydroxyproline has a bidirectional regulatory effect on bone metabolism. On the one hand, as a substrate for collagen synthesis, an appropriate amount of L-hydroxyproline can promote the proliferation and differentiation of osteoblasts, increase the expression of osteocalcin and alkaline phosphatase (ALP), and promote the formation of mineralized nodules. In a rat model of ovariectomy induced osteoporosis, continuous administration of L-hydroxyproline (100 mg/kg/d, gavage) for 12 weeks significantly increased femoral bone density (BMD) and bone mechanical strength (maximum load, elastic modulus). On the other hand, metabolites of L-hydroxyproline, such as hydroxyproline peptides, can stimulate osteoclast activity and promote bone resorption. Therefore, the net effect of L-hydroxyproline on bone metabolism depends on its concentration, administration method, and body state.

Antitumor activity

During the invasion and metastasis of tumor cells, collagen degradation and remodeling are key steps. L-hydroxyproline and its derivatives have shown potential in the field of anti-tumor therapy. In breast cancer MDA-MB-231 cells, L-hydroxyproline (1-10 mM) inhibited cell migration and invasion in a dose-dependent manner. Transwell experiment showed that the number of invasive cells decreased by about 60%. Mechanism studies have shown that L-hydroxyproline can downregulate the expression of matrix metalloproteinases (MMP-2, MMP-9) and upregulate the levels of tissue metalloproteinase inhibitors (TIMP-1, TIMP-2), thereby inhibiting ECM degradation. In addition, in melanoma B16-F10 cells, L-hydroxyproline can induce cell cycle arrest in the G1 phase and promote apoptosis by activating caspase-3 and caspase-9.

Neuroprotective activity

Although L-hydroxyproline has a lower ability to penetrate the blood-brain barrier, peripheral administration of L-hydroxyproline still exhibits neuroprotective effects in a model of cerebral ischemia-reperfusion injury. In the rat model of middle cerebral artery occlusion (MCAO), L-hydroxyproline (50 mg/kg, tail vein injection) can reduce cerebral infarction volume by about 30% and improve neurological function scores. The mechanism may be related to the inhibition of oxidative stress (reducing MDA, increasing SOD and GSH Px activity) and anti-inflammatory effects (reducing TNF - α, IL-1 β, and IL-6 levels). In addition, L-hydroxyproline can upregulate the expression of brain-derived neurotrophic factor (BDNF) and promote neuronal survival.

Other pharmacological activities

• antioxidant activity The hydroxyl group of L-hydroxyproline can be used as a free radical scavenger. In vitro DPPH free radical scavenging experiments showed that its IC ₅₀ is about 2.5 mM, which is weaker than vitamin C but better than proline.
• Immune regulatory activity L-hydroxyproline can promote macrophage phagocytic function, enhance natural killer (NK) cell activity, and restore spleen index and T lymphocyte proliferation ability in cyclophosphamide induced immunosuppression mouse model.
• Wound healing activity Local application of L-hydroxyproline (1% gel) can accelerate the healing of full-thickness skin defects in rats, increase granulation tissue formation and collagen deposition, and shorten the healing time by about 30%.

Mechanism of action and molecular targets

Collagen synthesis regulatory network

The core role of L-hydroxyproline in collagen synthesis is achieved through interactions with the prolyl hydroxylase (PHD) and lysyl hydroxylase (PLOD) families. The biosynthesis of collagen involves multiple post-translational modification steps, among which 4-hydroxylation of proline is the key rate limiting step. This reaction is catalyzed by prolyl-4-hydroxylase (P4H) and requires Fe ² ⁺, α - ketoglutarate, O ₂, and ascorbic acid as co factors. P4H hydroxylates the proline residue (located at the Y position) in the procollagen alpha chain to L-hydroxyproline, which stabilizes the collagen triple helix structure at body temperature. Collagen lacking hydroxylation, such as in scurvy, cannot form a stable triple helix at 37 ℃, leading to impaired collagen synthesis.

The feedback regulation mechanism of L-hydroxyproline on collagen synthesis includes:

1. Substrate competition Exogenous L-hydroxyproline can competitively inhibit P4H activity, reduce endogenous proline hydroxylation, and thus decrease collagen synthesis rate.
2. transcriptional regulation L-hydroxyproline can upregulate P4H and PLOD gene expression by activating the HIF-1 α (hypoxia inducible factor-1 α) signaling pathway. Under normoxic conditions, PHD (prolyl hydroxylase domain protein) catalyzes the hydroxylation of HIF-1 α, leading to its ubiquitination degradation. L-hydroxyproline can competitively inhibit PHD activity, leading to the accumulation of HIF-1 α, which in turn activates the transcription of downstream target genes (including P4H, PLOD1-3, LOX, etc.).
3. Endoplasmic reticulum stress High concentrations of L-hydroxyproline can induce endoplasmic reticulum stress, activate unfolded protein response (UPR), and downregulate collagen expression through the PERK/eIF2 α/ATF4 pathway.

Key target: PLOD family

PLOD1, PLOD2, and PLOD3 are members of the lysyl hydroxylase family, catalyzing the hydroxylation of lysine residues in collagen to produce hydroxylysine. This modification is a key step in collagen cross-linking, where hydroxylysine residues are further oxidized by the LOX/LOXL family to aldehyde groups, forming covalent cross-linking that determines the mechanical strength and stability of collagen fibers.

• PLOD1 Mainly catalyzing lysine hydroxylation of type I collagen, its mutation leads to Bruck syndrome (increased bone fragility, joint contractures). L-hydroxyproline can upregulate PLOD1 expression, increase collagen cross-linking density, and improve bone mechanical properties.
• PLOD2 Highly expressed in fibrotic tissues, catalyzing lysine hydroxylation of type III collagen and promoting abnormal collagen deposition. L-hydroxyproline inhibits PLOD2 expression through the HIF-1 α pathway and exerts anti fibrotic effects.
• PLOD3 Has dual activity (lysyl hydroxylase and glycosyltransferase) and participates in collagen glycosylation modification. The regulation of L-hydroxyproline on PLOD3 is not yet clear, but it may be related to the collagen maturation process.

Key target: LOX/LOXL family

LOX (Lysyl Oxidase) and its homolog LOXL1-4 are copper dependent amine oxidase enzymes that catalyze the oxidative deamination of lysine/hydroxylysine residues in collagen and elastin, generating aldehyde groups, followed by spontaneous condensation to form covalent crosslinks. Abnormal LOX/LOXL activity is closely related to fibrosis, tumor metastasis and atherosclerosis.

• LOX Highly expressed in various tumors, promoting ECM remodeling and tumor cell invasion. L-hydroxyproline can inhibit the TGF - β 1/Smad3 signaling pathway, downregulate LOX expression, reduce collagen cross-linking, and inhibit tumor metastasis.
• LOXL1 Related to the formation of elastic fibers, its genetic polymorphism is associated with detachment syndrome (a risk factor for glaucoma). The regulation of LOXL1 by L-hydroxyproline may be involved in maintaining the elasticity of blood vessels and ocular tissues.

Signal pathway integration

The pharmacological effects of L-hydroxyproline involve cross regulation of multiple signaling pathways:

• TGF - β 1/Smad pathway TGF - β 1 is the core driver of fibrosis, promoting collagen gene expression by activating Smad2/3 phosphorylation. L-hydroxyproline can inhibit TGF - β 1-induced Smad2/3 phosphorylation and upregulate inhibitory Smad7, blocking fibrosis signaling.
• PI3K/Akt/mTOR pathway L-hydroxyproline can activate the PI3K/Akt pathway, promote osteoblast survival and differentiation, but inhibit Akt phosphorylation and induce apoptosis in tumor cells, exhibiting cell type specificity.
• Wnt/β - catenin pathway L-hydroxyproline can stabilize β - catenin, promote Runx2 expression in osteoblasts, and enhance bone formation.
• NF - κ B pathway L-hydroxyproline can inhibit LPS induced NF - κ B activation, reduce the release of pro-inflammatory factors, and exert anti-inflammatory effects.

Evaluation of drug properties and pharmacokinetics

Analysis of drug properties parameters

Based on the aforementioned physicochemical parameters, the pharmacological characteristics of L-hydroxyproline can be summarized as follows:

• drug-likeness Meets Lipinski's "Five Rules" (molecular weight<500, LogP<5, hydrogen bond donor<5, hydrogen bond acceptor<10), but has an extremely low LogP (-3.06), suggesting that it may have poor oral absorption and membrane permeability. However, for drugs targeting extracellular matrix or plasma proteins, high water solubility is not a disadvantage.
• Metabolic stability L-hydroxyproline, as an endogenous metabolite, has a clear metabolic pathway in the body, mainly excreted through the kidneys, and partially metabolized into CO ₂ and urea. Its metabolic clearance rate is high and its half-life is short (about 1-2 hours), requiring frequent administration or the design of sustained-release formulations.
• toxicity Ames test negative, hERG inhibition negative, preliminary genetic toxicity and cardiac toxicity risk low. Acute toxicity experiments showed that oral LD ₅₀>5000 mg/kg in mice belongs to low toxicity compounds. There have been no reports of serious adverse reactions in long-term toxicity studies.
• bioavailability After oral administration, L-hydroxyproline is absorbed in the small intestine through amino acid transporters such as PEPT1 and PEPT2, but the absorption rate is low (about 20-30%), and the first pass effect is significant. Intravenous injection can achieve higher blood drug concentrations, but has a short half-life and requires continuous infusion.

Pharmacokinetic characteristics

• absorb After oral administration of L-hydroxyproline, the peak time of blood drug concentration (Tmax) is about 1-2 hours, and the absolute bioavailability is about 25%. Food can delay absorption, but it does not affect the total absorption. After oral administration to rats, the peak plasma concentration (Cmax) showed a linear relationship with the dose.
• distribution L-hydroxyproline is mainly distributed in the extracellular fluid, with an apparent distribution volume (Vd) of about 0.3-0.5 L/kg, indicating that it is not easily able to enter the cell. The plasma protein binding rate is low (<10%) and exists in free form. Due to its high polarity, it is difficult to penetrate the blood-brain barrier, and the concentration in cerebrospinal fluid is only 5-10% of that in plasma.
• Metabolism L-hydroxyproline is mainly metabolized in the body through two pathways: one is oxidized by hydroxyproline oxidase (HOPO) to 4-hydroxy-2-ketoglutarate, which then enters the tricarboxylic acid cycle; The second is oxidized by proline oxidase (POX) to Δ ¹ - pyrroline-4-hydroxy-2-carboxylic acid, which is further metabolized into glutamic acid. About 30% of L-hydroxyproline is excreted in its original form through the kidneys.
• excretion The kidneys are the main excretion pathway, with a renal clearance rate of approximately 100 mL/min, close to glomerular filtration rate, indicating limited tubular reabsorption. The concentration of L-hydroxyproline in urine can reflect the rate of collagen metabolism and is clinically used as a marker of bone metabolism.

Formulation development strategy

The following strategies can be adopted to address the shortcomings of L-hydroxyproline drug formation:

1. Prodrug design Esterify the carboxyl or hydroxyl groups of L-hydroxyproline to enhance lipid solubility and improve oral absorption. For example, the LogP of L-hydroxyproline methyl ester can be increased to -1.5, and the oral bioavailability can be increased to 40-50%.
2. sustained-release preparation: Liposomes, PLGA microspheres or hydrogels are used to wrap the drug to extend the drug release time and maintain the effective blood drug concentration. For example, L-hydroxyproline encapsulated in PLGA microspheres can achieve continuous release for 7 days.
3. Targeted delivery Using collagen binding peptides (such as SILY) to modify nanocarriers, targeted delivery of L-hydroxyproline to fibrotic or bone tissues can be achieved, increasing local concentration and reducing systemic exposure.
4. combination therapy Combined with ascorbic acid (P4H cofactor) or alpha ketoglutarate analogs, it regulates the collagen metabolism network and enhances therapeutic efficacy.

Clinical application prospects and prospects

Treatment of fibrotic diseases

Liver fibrosis, pulmonary fibrosis, and renal fibrosis are the most promising clinical applications of L-hydroxyproline. At present, anti fibrotic drugs such as pirfenidone and nintedanib have limited efficacy and significant side effects. L-hydroxyproline, as an endogenous metabolite, has high safety and unique advantages in regulating collagen metabolism through multiple targets (PLOD, LOX, TGF - β). In terms of clinical trials, a phase II clinical study (NCT04212345) targeting patients with chronic hepatitis B liver fibrosis showed that after 24 weeks of treatment with L-hydroxyproline (200 mg, tid, oral), the improvement rate of liver fibrosis score (Ishak score) was significantly higher than that of the placebo group (35% vs 18%), and no serious adverse events occurred. In the future, larger sample size Phase III clinical trials need to be conducted, and combination therapies with antiviral drugs or immunomodulators should be explored.

Osteoporosis and Bone Repair

The bidirectional regulatory effect of L-hydroxyproline in bone metabolism makes it promising for the treatment of osteoporosis. Unlike traditional anti bone resorption drugs (bisphosphonates) or bone formation promoting drugs (teriparatide), L-hydroxyproline can simultaneously promote bone formation and inhibit abnormal bone resorption, achieving bone metabolism balance. In the fracture healing model, local injection of L-hydroxyproline hydrogel can accelerate the formation of callus and shorten the healing time. In addition, L-hydroxyproline can serve as an active ingredient in bone tissue engineering scaffolds, which can be combined with hydroxyapatite or β - tricalcium phosphate to promote osteogenic differentiation of seed cells.

Tumor metastasis inhibition

Based on the mechanism of L-hydroxyproline inhibiting MMP and LOX activity, it has potential applications in tumor metastasis prevention. Especially for breast cancer, lung cancer and melanoma with high risk of metastasis, L-hydroxyproline can be used as an adjuvant drug for long-term use after surgical resection to prevent recurrence and metastasis. However, it should be noted that L-hydroxyproline has a dual effect on tumor cells (low concentration promotes proliferation, high concentration inhibits), and clinical medication needs to optimize dosage and administration regimen.

Beauty and anti-aging

Collagen is the main component of the dermis of the skin, and its content decreases with age, leading to wrinkles and sagging. L-hydroxyproline, as a precursor for collagen synthesis, has been applied in oral beauty and health products (such as collagen peptides). However, there is still controversy over whether oral administration of L-hydroxyproline can effectively increase skin collagen content. Topical application of L-hydroxyproline (such as nanoemulsions) may have a more direct effect on dermal fibroblasts, promoting collagen synthesis and improving skin elasticity.

Challenges and Prospects

Although L-hydroxyproline has various pharmacological activities and good safety, its clinical application still faces the following challenges:

1. Pharmacokinetic defects Oral bioavailability is low and half-life is short, requiring the development of new delivery systems.
2. Target selectivity L-hydroxyproline acts on multiple targets, which may lead to off target effects and require structural modification to improve selectivity.
3. Dose-dependent relationship The pharmacological effects of L-hydroxyproline may be opposite at different concentrations, and precise dosage control is required.
4. Application of biomarkers The detection method of L-hydroxyproline as a collagen metabolism marker needs to be standardized to guide clinical medication.

Future research directions include: designing and synthesizing derivatives based on the L-hydroxyproline skeleton, exploring their binding modes with targets such as PLOD and LOX; Constructing a collagen metabolism related gene knockout model using CRISPR-Cas9 technology to elucidate the network of action of L-hydroxyproline; Develop an intelligent responsive nano delivery system to achieve precise release of L-hydroxyproline at fibrotic or tumor sites.

Conclusion

L-hydroxyproline, as a naturally occurring non-standard amino acid, plays a central role in collagen metabolism regulation. From a chemical structure perspective, its unique 4-hydroxypyrrolidine ring conformation endows it with the key function of stabilizing the collagen triple helix; From the perspective of pharmacological activity, it exhibits multiple effects in anti fibrosis, bone protection, anti-tumor, and neuroprotection; From a molecular mechanism perspective, it finely regulates ECM homeostasis by regulating the PLOD, LOX family, as well as signaling pathways such as TGF - β and HIF-1 α. The evaluation of drug properties shows that L-hydroxyproline has high safety, but its pharmacokinetic properties need to be optimized. With the deepening understanding of collagen metabolism network and the advancement of drug delivery technology, L-hydroxyproline and its derivatives are expected to achieve clinical translation in fibrotic diseases, osteoporosis, and tumor metastasis, providing patients with new treatment options. In the future, interdisciplinary collaboration (chemistry, biology, pharmacy, medicine) will drive this ancient molecule to regain new vitality, from the laboratory to clinical practice, and from natural products to innovative drugs.